TY - JOUR
T1 - Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts
AU - Shearer, William T.
AU - Fleisher, Thomas A.
AU - Buckley, Rebecca H.
AU - Ballas, Zuhair
AU - Ballow, Mark
AU - Blaese, R. Michael
AU - Bonilla, Francisco A.
AU - Conley, Mary Ellen
AU - Cunningham-Rundles, Charlotte
AU - Filipovich, Alexandra H.
AU - Fuleihan, Ramsay
AU - Gelfand, Erwin W.
AU - Hernandez-Trujillo, Vivian
AU - Holland, Steven M.
AU - Hong, Richard
AU - Lederman, Howard M.
AU - Malech, Harry L.
AU - Miles, Stephen
AU - Notarangelo, Luigi D.
AU - Ochs, Hans D.
AU - Orange, Jordan S.
AU - Puck, Jennifer M.
AU - Routes, John M.
AU - Stiehm, E. Richard
AU - Sullivan, Kathleen
AU - Torgerson, Troy
AU - Winkelstein, Jerry
N1 - Funding Information:
Supported by the Intramural Research Program of the National Institutes of Health Clinical Center (T.A.F.) and the National Institute of Allergy and Infectious Diseases (S.M.H. and H.L.M.). No official endorsement of support by the National Institutes of Health or the Department of Health and Human Services is intended or should be inferred.
Funding Information:
Disclosure of potential conflict of interest: T. A. Fleisher is employed by the National Institutes of Health (NIH) and has received royalties as the coeditor of a clinical immunology textbook. R. H. Buckley is employed by the Duke University Medical Center and has stock/stock options in various entities. Z. Ballas has received research support from the NIH , has received consultancy fees from Immune Deficiency, and receives royalties from UpToDate. M. Ballow has received consultancy fees from Baxter and CSL Behring; is employed by USF Health and Windom Allergy; has received research support from CSL Behring ; has received lecture fees from Avant, Grifols, and CSL Behring; and has received payment for manuscript preparation from Elsevier and UpToDate. R. M. Blaese has received consultancy fees from the Immune Deficiency Foundation (Consulting Medical Director and MAC member). F. A. Bonilla has received consultancy fees from CSL Behring, has received lecture fees from Pediatric Update, has received royalties from UpToDate, has received travel fees from the Immune Deficiency Foundation, and is a member of the Blood Product Advisory Committee (US Food and Drug Administration). E. W. Gelfand has received consultancy fees from Biotest Pharmaceutical Corporation and CSL Behring, has received research support from the NIH, and is employed by National Jewish Health. V. Hernandez-Trujillo has received consultancy fees from Sanofi and Baxter; has received lecture fees from Merck, Sanofi, Baxter, and CSL; has received travel fees from Baxter; is a spokesperson for Sanofi; and is a spokesperson and member of the Claritin Council for Merck. S. Miles is a voluntary board member for a medical advisory committee. L. D. Notarangelo is a board member for Meyer Pediatric University Hospital in Florence, Italy, and for a program in Molecular and Cellular Medicine; is employed by Boston Children's Hospital; has received research support from the NIH and March of Dimes; and receives royalties from UpToDate. H. D. Ochs is a board member for DSMC and Sigma Tau and has received travel fees from CSL Behring. J. S. Orange has received consultancy fees from Baxter, CSL Behring, Octapharma, Atlantic Research, Grifols, and BPL; has provided expert testimony for the State of Arizona; has received research support from CSL Behring ; has received lecture fees from Baxter; and has received royalties from UpToDate. J. M. Puck has received research support from the NIH and has received travel fees from the NIH (USID Net NIH U24 P0027559 and PIDTC NIH U54 A1082973). E. R. Stiehm has received consultancy fees from UpToDate, is employed by the UCLA Medical Center, has received lecture fees and payment for manuscript preparation, and has stock/stock options not related to this work. K. Sullivan has received consultancy fees from the Immune Deficiency Foundation and receives royalties from UpToDate. T. Torgerson has received consultancy fees from Baxter Biosciences and BD Bioscience, has received research support from Baxter Biosciences and CSL Behring , has received lecture fees from Baxter Biosciences, and has received lecture fees from Baxter Biosciences. The rest of the authors declare that they have no relevant conflicts of interest.
PY - 2014/4
Y1 - 2014/4
N2 - The present uncertainty of which live viral or bacterial vaccines can be given to immunodeficient patients and the growing neglect of societal adherence to routine immunizations has prompted the Medical Advisory Committee of the Immune Deficiency Foundation to issue recommendations based on published literature and the collective experience of the committee members. These recommendations address the concern for immunodeficient patients acquiring infections from healthy subjects who have not been immunized or who are shedding live vaccine-derived viral or bacterial organisms. Such transmission of infectious agents can occur within the hospital, clinic, or home or at any public gathering. Collectively, we define this type of transmission as close-contact spread of infectious disease that is particularly relevant in patients with impaired immunity who might have an infection when exposed to subjects carrying vaccine-preventable infectious diseases or who have recently received a live vaccine. Immunodeficient patients who have received therapeutic hematopoietic stem transplantation are also at risk during the time when immune reconstitution is incomplete or while they are receiving immunosuppressive agents to prevent or treat graft-versus-host disease. This review recommends the general education of what is known about vaccine-preventable or vaccine-derived diseases being spread to immunodeficient patients at risk for close-contact spread of infection and describes the relative risks for a child with severe immunodeficiency. The review also recommends a balance between the need to protect vulnerable subjects and their social needs to integrate into society, attend school, and benefit from peer education.
AB - The present uncertainty of which live viral or bacterial vaccines can be given to immunodeficient patients and the growing neglect of societal adherence to routine immunizations has prompted the Medical Advisory Committee of the Immune Deficiency Foundation to issue recommendations based on published literature and the collective experience of the committee members. These recommendations address the concern for immunodeficient patients acquiring infections from healthy subjects who have not been immunized or who are shedding live vaccine-derived viral or bacterial organisms. Such transmission of infectious agents can occur within the hospital, clinic, or home or at any public gathering. Collectively, we define this type of transmission as close-contact spread of infectious disease that is particularly relevant in patients with impaired immunity who might have an infection when exposed to subjects carrying vaccine-preventable infectious diseases or who have recently received a live vaccine. Immunodeficient patients who have received therapeutic hematopoietic stem transplantation are also at risk during the time when immune reconstitution is incomplete or while they are receiving immunosuppressive agents to prevent or treat graft-versus-host disease. This review recommends the general education of what is known about vaccine-preventable or vaccine-derived diseases being spread to immunodeficient patients at risk for close-contact spread of infection and describes the relative risks for a child with severe immunodeficiency. The review also recommends a balance between the need to protect vulnerable subjects and their social needs to integrate into society, attend school, and benefit from peer education.
KW - Live viral and bacterial vaccines
KW - cellular immune reconstitution
KW - primary immunodeficiency disease
KW - severe combined immunodeficiency disease
UR - http://www.scopus.com/inward/record.url?scp=84897458695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897458695&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2013.11.043
DO - 10.1016/j.jaci.2013.11.043
M3 - Article
C2 - 24582311
AN - SCOPUS:84897458695
SN - 0091-6749
VL - 133
SP - 961
EP - 966
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 4
ER -